View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
DOJ/DEA | RIN: 1117-AB73 | Publication ID: Fall 2021 |
Title: Medications to Prevent Narcotic Opioid Withdrawal Symptoms in Hospitals | |
Abstract:
DEA proposes to revise the existing regulations found in 21 CFR 1306.07(b), regarding the administration of narcotic drugs in hospitals to prevent or mitigate opioid withdrawal, as instructed by Congress in Public Law 116-215 (effective December 11, 2020). The existing regulation is inadequate for emergency treatment purposes, as practitioners are prohibited from administering narcotic drugs, for the purpose of relieving acute withdrawal symptoms, to a patient for not more than one day at a time for not more than three consecutive days. In accordance with the statute, DEA proposes to allow practitioners to provide up to a five-day supply of opioid medications at one time to prevent or mitigate opioid withdrawal. DEA may request input on whether there is reason to allow practitioners to dispense medications for up to five additional days if there is still a need after the conclusion of the initial three-day period. |
|
Agency: Department of Justice(DOJ) | Priority: Other Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: 21 CFR 1306 | |
Legal Authority: 21 U.S.C. 821, 827, 871(b) |
Legal Deadline:
|
||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: Businesses | Federalism: No |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Scott A. Brinks Section Chief, Regulatory Drafting and Support Section, Diversion Control Division Department of Justice Drug Enforcement Administration 8701 Morrissette Drive, Springfield, VA 22152 Phone:571 362-8209 Email: scott.a.brinks@dea.gov |